<?xml version="1.0" encoding="UTF-8"?>
<p>So far, lopinavir/ritonavir has been the only antiviral agent undergoing a major randomized clinical trial. Lopinavir/ritonavir is an approved oral combination agent for the treatment of HIV. The association has been previously used in SARS and retrospective studies seemed to suggest a reduction in mortality and intubation rates in patients who received this treatment [
 <xref rid="B142-vaccines-08-00224" ref-type="bibr">142</xref>]. The first published randomized trial in Covid-19 was open-label and included 199 hospitalized adult patients with confirmed SARS-CoV-2 infection. No adjunctive benefit in the time to clinical improvement, mortality rates at 28 days and viral RNA load at various time point was observed in patients who received lopinavir/ritonavir (n = 99) compared to patients who were managed as per standard of care (n = 100) [
 <xref rid="B143-vaccines-08-00224" ref-type="bibr">143</xref>].
</p>
